Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Korro Bio has raised $85.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Korro Bio's investors include New Enterprise Associates, Balyasny Asset Management, Blue Owl, Point72, Cormorant Asset Management.
Korro Bio is headquartered in Cambridge, United States.
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Korro Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Korro Bio — Funding & Investors." VCBacked, March 9, 2026, https://www.vcbacked.co/company/korro-bio. Accessed August 14, 2026.
VCBacked. (2026). Korro Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/korro-bio
{{cite web |title=Korro Bio — Funding & Investors |url=https://www.vcbacked.co/company/korro-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated